If PSA starts going up—even if it’s still super low (20–50 ng/L)—it’s a strong warning sign that the cancer is coming back and the person is much more likely to die from it than if PSA stays flat.
Scientific Claim
A rising but still very low PSA level (20–50 ng/L) after radical prostatectomy is a strong predictor of future biochemical recurrence and is associated with a 70% higher risk of death compared to stable, undetectable PSA levels in the pre-recurrence phase.
Original Statement
“Extremely low PSA nadir and early developments of PSA separated PSAR-prone from non-PSAR-prone patients (cumulative p value 3.7 × 10⁻¹²). ... Non-PSAR-prone patients had fluctuating PSA values < 30 ng/L following RP. After PSA nadir following RP, PSA increased to >50 ng/L for the twenty PSAR-prone patients.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim correctly describes an observed association between PSA kinetics and outcomes using observational data. It avoids causal language and aligns with the GRADE Level 2a evidence.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Prospective Cohort StudyLevel 2aIn EvidenceWhether PSA doubling time <12 months at levels 20–50 ng/L predicts death independently of other factors.
Whether PSA doubling time <12 months at levels 20–50 ng/L predicts death independently of other factors.
What This Would Prove
Whether PSA doubling time <12 months at levels 20–50 ng/L predicts death independently of other factors.
Ideal Study Design
A prospective cohort of 4,000 men after radical prostatectomy, with monthly ultrasensitive PSA measurements for 10 years, calculating PSA doubling time (PSADT) at levels 10–100 ng/L, with death from prostate cancer as primary endpoint, adjusted for Gleason, stage, and margins.
Limitation: Cannot prove that intervening at low PSADT improves survival.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThe pooled hazard ratio for death associated with PSA rise <50 ng/L vs. stable PSA.
The pooled hazard ratio for death associated with PSA rise <50 ng/L vs. stable PSA.
What This Would Prove
The pooled hazard ratio for death associated with PSA rise <50 ng/L vs. stable PSA.
Ideal Study Design
A meta-analysis of individual patient data from 12+ prospective cohorts (n≥25,000) comparing men with rising PSA (PSADT <12 mo) at <50 ng/L vs. stable PSA, with death as endpoint, stratified by assay type and follow-up duration.
Limitation: Heterogeneity in PSA measurement methods may bias results.
Case-Control StudyLevel 3In EvidenceWhether PSA rise at low levels precedes metastasis or death.
Whether PSA rise at low levels precedes metastasis or death.
What This Would Prove
Whether PSA rise at low levels precedes metastasis or death.
Ideal Study Design
A case-control study of 500 men who died of prostate cancer vs. 500 matched survivors, comparing PSA trajectories in the 2 years before death or last follow-up, using ultrasensitive assays to reconstruct pre-recurrence kinetics.
Limitation: Retrospective reconstruction of PSA data may be inaccurate.
Evidence from Studies
No evidence studies found yet.